Xenetic Biosciences, Inc. (OTCQB: XBIO) is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for the development of next generation biologic drugs that extend the efficacy, safety and half-life of biologic drugs and OncoHist™ for the development of novel oncology drugs focused on orphan indications.
Xenetic is working with Baxter International Inc. (NYSE: BAX), one of the Company’s largest shareholders, through an exclusive research, development and license agreement to develop a novel series of polysialylated blood coagulation factors, including a next generation Factor VIII. This collaboration relies on the PolyXen technology to conjugate PSA to therapeutic blood-clotting factors, with the goal of improving the pharmacokinetic profile and extending the active life of these biologic molecules.
Xenetic is developing a biopharmaceutical pipeline with a multi-billion dollar market potential.
Xenetic has collaborations with leading global biopharma companies, including Baxter International